Queen's Award Received in 2021 ISO 9001 Certified Delivered over 1,000,000 bio-reagents to life science researchers Trusted by Life Science Communities
Cart summary

You have no items in your shopping cart.

SKLB-23bb

SKU: orb1220766

Description

SKLB-23bb is an orally bioavailable HDAC6-selective inhibitor and also has microtubule-disrupting ability.

Images & Validation

Key Properties

CAS Number1815580-06-3
MW396.44
Purity>98% (HPLC)
FormulaC21H24N4O4?
SMILESCOc1ccc(cc1OCCCC(=O)NO)N(C)c1nc(C)nc2ccccc12
TargetHDAC
SolubilityDMSO:32 mg/mL (80.72 mM)

Bioactivity

In Vivo
SKLB-23bb (Compound 23bb) reduces the tumor growth in both the hematological tumor MV4-11 xenograft model and solid tumor HCT116 xenograft model. The significant antitumor activities are observed by intravenous administration of SKLB-23bb at 50 mg/kg on MV4-11 and HCT116 xenograft models. The growth of MV4-11 and HCT116 cancer cell xenografts is suppressed by 55.0% and 76.3% (percent of tumor mass change [TGI] values) after iv administration of SKLB-23bb at 50 mg/kg. The HCT116 xenograft model is also established to investigate the antitumor activity of oral administration of SKLB-23bb. The TGI value of oral administration of SKLB-23bb (25 mg/kg) on HCT116 xenograft model is 60.4%, which is superior to the SAHA group (100 mg/kg, 59.2%). Additionally, the body weight decrease is acceptable and no other adverse effects are observed upon treatment with SKLB-23bb. Low clearance (CL = 7.008 L/kg per hour for iv, CL = 12.877 L/kg per hour for po) and long terminal half-life (t1/2 = 7.658 h for iv, t1/2 = 9.62 h for po) are observed in SKLB-23bb. The oral bioavailability of SKLB-23bb is excellent in rats and the bioavailability is up to 47.0%.
In Vitro
SKLB-23bb (Compound 23bb) presents low nanomolar antiproliferative effects against panel of cancer cell lines. The antiproliferative activity is ton human malignant melanoma A375 cells and cervical cancer HeLa cells, SKLB-23bb shows the most potent activities with IC50 values of 50 and 49 nM on A375 and HeLa cells, respectively. The antiproliferative activities against 11 kinds of hematological tumors (myelomaU266, RPMI8226 cells, human leukemia MV4-11, K562 cells, and human B cell lymphoma Ramos cells) or solid tumors (ovarian cancer A2780s, SKOV-3 cells, breast cancer SKBR3 cells, liver cancer HepG2 cells, lung cancer H460, A549 cells, cervical cancer HeLa cells and colon cancer HCT116, HT29 cells) cell lines of SKLB-23bb are evaluated by MTT, and the SAHA and ACY-1215 are as positive control. SKLB-23bb shows significant antiproliferative potential with the IC50 values ranging from 14 to 104 nM in these tumor cell lines.

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Similar Products

  • SKLB-23bb [orb1301451]

    ≥98% (May vary between batches)

    1815580-06-3

    396.44

    C21H24N4O4

    5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 1 mg, 1 ml x 10 mM (in DMSO), 200 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Protocol Information

Available Sizes

Select a size below

200 mg
500 mg
2 mg
$ 260.00
5 mg
$ 500.00
10 mg
$ 720.00
25 mg
$ 1,170.00
50 mg
$ 1,640.00
100 mg
$ 2,200.00